Introduction
Induction of type I interferons and pro-inflammatory cytokines represents the first line of host defense against viruses [1] . This antiviral response is initiated by germline-encoded pattern recognition receptors (PRRs). One of the PRR families is the Toll-like receptors (TLRs, including TLR3, TLR7-TLR8 and TLR9) that are predominantly expressed in the endosome of immune cells. Upon virus infection, these receptors detect the presence of viral nucleic acids in topologically extracellular compartment and recruit adaptor proteins (TRIF and MyD88), which ultimately activate transcription factors IRF3/IRF7 and NF-κB [2] . In contrast, retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) have recently been characterized as ubiquitous sensors for detecting cytosolic RNA viruses during primary responses of host cells [3] [4] [5] [6] [7] [8] . Once RIG-I/MDA5 sense the viral RNAs, they trigger the formation of a signal complex on the mitochondrial outer membrane, which includes adaptor proteins MAVS/IPS1/VISA/Cardif, TRAF3 and TRADD [9] [10] [11] [12] [13] . This ultimately leads to the activation of TANK-binding kinase 1 (TBK1), which then phosphorylates interferon regulatory factor 3 (IRF3) on a series of Ser/Thr residues at its C-terminus [14] [15] [16] . In turn, IRF3 dimerizes, translocates into nucleus and recruits p300/CBP, which ultimately results in the early production of IFN-β and subsequent establishment of antiviral state [17] [18] [19] . Several proteins have also been reported to regulate this signaling pathway. In addition, MAVS signal complex could activate IKK complex and NF-κB.
Notably, MAVS per se localizes on the outer membrane of mitochondria through its C-terminal transmembrane (TM) domain [11] . In contrast, the rest of the reported components in the MAVS signal complex reside in the cytosol. Although TRAF3/TRADD are implicated to associate with MAVS, there is no direct interaction between MAVS and TBK1/IRF3 [20] [21] [22] . It remains largely unknown how MAVS relays the activation signal to TBK1/IRF3.
Although mitochondria encode some genetic information, almost all the mitochondrial proteins are synthesized in the cytosol and then transported into corresponding compartments in mitochondria. Recent breakthroughs on mitochondrial protein targeting demonstrate that translocases of outer membrane (Tom) complex is responsible for initial recognition of mitochondrial preproteins from the cytosol [23, 24] . Tom70 and Tom20 are characterized as major docking receptors to mediate the recognition by different mechanisms. Importantly, a subgroup of mitochondrial pre-proteins is constitutively associated with chaperone Hsp90, which is revealed to deliver this category of proteins to Tom70 [25, 26] . In contrast, Tom20 recognizes classical N-terminal signal peptides (positively charged amphipathic helices) found in most of the mitochondrial pre-proteins and this mechanism is Hsp90-independent [27] . Tom70 (608 aa) is anchored to the mitochondrial outer membrane via its Nterminal TM segments (1-60 aa). The remaining part of Tom70 is largely hydrophilic and exposed to the cytosol, which include a clamp domain (110-235 aa) and a core domain (250-608 aa). The clamp and core domains are implicated to mediate its interactions to Hsp90 and mitochondrial pre-proteins, respectively [25] . It is intriguing to address if Tom70 plays novel function(s) besides its role in the mitochondrial protein transport.
An unresolved issue is that why mitochondria is selected as the platform for intracellular antiviral signaling. Also, a critical missing link exists from MAVS to TBK1/IRF3. Therefore, we use proteomics approach to identify novel proteins in the MAVS signal complex. To our surprise, Tom70 is found to interact specifically with MAVS during RNA virus infection. In this study, we demonstrate that Tom70 plays an essential role in the antiviral response. Ectopic expression of Tom70 potentiates IRF3-mediated gene expression. Conversely, depletion of Tom70 expression by RNA interference drastically decreases IFN-β production, thus permitting viral infection and replication. Mechanistically, the clamp domain (R192) of Tom70 interacts with the C-terminal motif (EEVD) of Hsp90, thereby recruiting TBK1/IRF3 to mitochondria. Significantly, disruption of this interaction or mislocation of Tom70 sharply impairs the activation of TBK1 and IRF3. Taken together, these data indicate that Tom70 is a critical adaptor bridging TBK1/IRF3 to MAVS. The current study sheds new light on the evolutionary integration of mitochondria with antiviral innate immunity.
Results

Tom70 is a new component of MAVS signal complex on mitochondria
Given that cytosolic TBK1/IRF3 do not interact directly with mitochondrial MAVS, we reasoned that there might be unknown adaptor protein(s) on the outer membrane of mitochondria linking TBK1/IRF3 to MAVS during virus infection. To address this possibility, we expressed Flag-MAVS in HEK293T cells and then treated them with or without Sendai virus (SeV) for 2 h. After fractionation of the mitochondrial pellets, immunoprecipitation and silver staining of MAVS protein complex revealed a specific band (~80 kDa), the amount of which apparently increased upon SeV stimulation ( Figure 1A) . Mass spectrometry analysis unequivocally identified the translocase of outer membrane 70 (Tom70; 31 unique peptides covering 57.4% of the whole protein, data not shown), and immunoblotting of the same precipitates by Tom70 polyclonal antibody confirmed this observation ( Figure 1B ). Apparently, virus infection did not affect the expression of Tom70 ( Figure 1C ). Both confocal imaging and sub-cellular fractionation confirmed that Tom70 and Tom20 were exclusively expressed on mitochondria ( Figures 1D and 4E ). Immunoprecipitation assays revealed that Tom70 also associated with TRADD, TRAF6 and STING, but not with CARD9, suggesting that Tom70 is a novel component of the MAVS signalsome ( Figure  1E and 1F) [12, 13, [30] [31] [32] .
Exogenous expression of Tom70 potentiates IRF3-mediated gene expression
To explore the potential functional relevance of Tom70-MAVS interaction, we investigated whether Tom70 had any impact on IRF3 activation status. As shown in Supplementary information, Figure S1A and S1B, introduction of Tom70 into HEK293 cells potentiated the induction of both IFN-β-and PRDIII-I-luciferase reporters in a dose-dependent manner upon SeV infection or poly(I:C) stimulation. Also, Tom70 enhanced the expression of ĸB-luciferase reporter under the same condition (Supplementary information, Figure S1A and S1B). As a control, overexpression of Tom20 did not influence the IFN-β-or PRDIII-I-luciferase reporters (Supplementary information, Figure S1C and S1D). Furthermore, we measured the induction of endogenous mRNAs from IRF3-responsive genes (including IFN-β, ISG56 and Rantes) by Q-PCR, after stimulating the cells by SeV infection or poly(I:C) transfection in the presence of exogenously expressed Tom70. Significantly, Tom70 potentiated the expression of endogenous IRF3-responsive genes (Figure 2A and 2B) . In contrast, Tom20 had no ef- fect on the mRNA transcription of IRF3-regulated genes. In addition, ectopic expression of Tom70 displayed no effect on TRIF-mediated activation of IFN-β-luciferase reporters or Wnt signaling (Supplementary information, Figure S1E and S1F).
To make it more physiologically relevant, we examined whether Tom70 regulated IRF3-induced gene expression in primary cells. Consistently, ectopic expression of Tom70 markedly potentiated the expression of endogenous IRF3-responsive genes both in BMDMs (bone marrow-derived macrophages; Figure 2C ) and BMDCs (bone marrow-derived dendritic cells; Figure  2D ). In addition, Tom70 also potentiated the expression of endogenous NF-κB-responsive genes (Supplementary information, Figure S2 ). Collectively, these data suggest that Tom70 synergizes the activation of intracellular antiviral signal transduction.
Knockdown of Tom70 impairs the activation of IRF3
Alternatively, we used the knockdown approach to probe the function of Tom70, using Tom20 as a negative control. The effective siRNA oligonucleotides were screened out, which could reduce the endogenous protein levels of Tom70 (Supplementary information, Figure  S3A ) or Tom20 (Supplementary information, Figure  S3B ) by >90%. Initially, luciferase assay was used to evaluate the effect of Tom70 knockdown on IRF3 activation in HEK293 cells. As expected, knockdown of endogenous Tom70 drastically inhibited the expression of both IFN-β-and PRDIII-I-luciferase reporters induced by SeV (Supplementary information, Figure S3C ) or transfection of poly(I:C) (Supplementary information, Figure S3D ). Similarly, ĸB-luciferase reporter activity was also impaired by Tom70 knockdown under the same condition (Supplementary information, Figure S3C and S3D). In contrast, both Tom20 siRNA and Tom70mt siRNA, a mutant form of Tom70 siRNA with no silencing activity, failed to do so (Supplementary information, Figure S3C and S3D) .
We went on to analyze in HEK293 cells, the effect of Tom70 knockdown on the induction of endogenous IRF3-responsive genes, stimulated by SeV or poly(I:C). Again, Tom70 knockdown dramatically inhibited the transcription of IRF3-responsive mRNAs, whereas neither Tom20 nor Tom70mt siRNA had any inhibitory effect ( Figure 3A and 3B ). In addition, silencing of Tom70 displayed no effect on TRIF-mediated activation of IFN-β-luciferase reporters (Supplementary information, Figure S3E ) or Wnt signaling (Supplementary information, Figure S3F ). We also isolated P-Mφ (peritoneal macrophage), BMDM and BMDC, and respectively transfected these cells with indicated siRNAs followed by SeV infection. Consistently, knockdown of Tom70 but not Tom20 markedly attenuated SeV-induced expression of endogenous IRF3-responsive genes in BMDM ( Figure  3C ), BMDC ( Figure 3D ) as well as P-Mφ ( Figure 3E ). In addition, reduction of endogenous Tom70 displayed the same effects on NF-κB activation (Supplementary information, Figure S4 ).
To rule out potential off-target effects of the Tom70 siRNA, an RNAi-resistant Tom70 construct (rTom70) was generated, in which silent mutations were introduced into the sequence targeted by the siRNA without changing the amino acid sequence of the protein. HEK293 cells were first transfected with control or Tom70 siRNA followed by the transfection of control or rTom70 plasmids as indicated, respectively. Then the induction of IFN-β mRNA was measured by Q-PCR after SeV treatment. As shown in Figure 5F , rescue experiments indicated that SeV-stimulated IFN-β mRNA induction was restored by introducing rTom70 into Tom70 knockdown cells. Collectively, these results strongly suggest that Tom70 is a positive regulator of IRF3 activation.
Tom70 functions downstream of MAVS and upstream of TBK1
To delineate the topology of Tom70 in RIG-I/MAVS/ TBK1/IRF3 signaling pathway, we noticed that exogenous expression of RIG-I N-terminal tandem CARD domains (RIG-I-N) or MAVS could induce the expression of IFN-β-luciferase reporters, and this induction was markedly potentiated by the ectopic expression of Tom70 ( Figure 4A ). Consistently, knockdown of Tom70 impaired the expression of IFN-β reporter under the same condition ( Figure 4B ). However, neither ectopic expression nor knockdown of Tom70 had any effect on the induction of IFN-β reporter, when stimulating with exogenous TBK1 (Figure 4A and 4B).
To substantiate the above observations, we investigated the kinase activity of TBK1 and phosphorylation status of IRF3 during SeV infection, when endogenous Tom70 was knocked down. As shown in Figure 4C , decrease in endogenous Tom70 expression caused significant loss of the kinase activities of TBK1, whereas this effect did not apply to Tom20 knockdown. Furthermore, reduction of endogenous Tom70 expression also resulted in the significant attenuation of IRF3 phosphorylation induced by SeV ( Figure 4D ). Taken together, these results suggest that Tom70 functions downstream of MAVS and upstream of TBK1.
As Tom70 is involved in mitochondrial protein transport, it was possible that Tom70 affected the sub-cellular location of MAVS or the integrity of mitochondria. We utilized both sub-cellular fractionation methods and confocal imaging techniques to check where MAVS localized in the absence of Tom70. The steps to isolate the crude mitochondria pellets were shown in the diagram ( Figure 4E amine methylester (TMRM) staining indicated that the mitochondrial membrane potential remained intact when silencing endogenous Tom70. In contrast, the mitochondrial inhibitor carbonyl cyanide m-chlorophenyl hydrazone (CCCP) dramatically blocked TMRM accumulation in mitochondria by disturbing mitochondrial membrane potential ( Figure 4H ). Collectively, Tom70 plays a specific role during the primary induction of type-I interferons.
Tom70 interacts with MAVS during virus infection or poly(I:C) stimulation
To confirm the specific interactions between MAVS and Tom70, HA-Tom70 and Flag-MAVS were cotransfected into HEK293T cells, which were then treated by SeV infection or poly(I:C) transfection for 0-5 h. Cell lysates were immunoprecipitated with either mouse control IgG or anti-Flag antibody. As expected, HA-Tom70 could be co-immunoprecipitated with Flag-MAVS, but not with control IgG ( Figure 5A ). Apparently, SeV or poly(I:C) challenge could enhance the affinity between Flag-MAVS and HA-Tom70 ( Figure 5A ). Consistently, endogenous Tom70 co-immunoprecipitated with endogenous MAVS, and this interaction was also enhanced upon SeV stimulation or poly(I:C) transfection ( Figure 5B ).
To explore the functional significance of this interaction between Tom70 and MAVS, we generated two mislocation mutants of Tom70. Tom70(∆TM) was constructed by deleting the N-terminal transmembrane domain, and Tom70(ER-TM) was constructed by replacing its transmembrane domain with a targeting sequence to endoplasmic reticulum (ER; Figure 5C upper panel). Tom70(∆TM) and Tom70(ER-TM) were confirmed to localize in the cytosol or ER, respectively ( Figure 5C middle and lower panel). Interestingly, Tom70(∆TM) ( Figure  5D ) and Tom70(ER-TM) (data not shown) failed to interact with wild-type MAVS. Conversely, MAVS(∆TM), a previously reported mutant that localizes in the cytosol, also could not interact with wild-type Tom70 ( Figure  5D ). These data indicate that the transmembrane domains of both MAVS and Tom70 are essential to mediate their interactions during viral infection.
To corroborate the activity of the mislocation mutants, neither Tom70(∆TM) nor Tom70(ER-TM) could potentiate the expression of IFN-β induced by SeV or poly(I:C) ( Figure 5E ). Furthermore, the corresponding RNAi-resistant constructs of Tom70(∆TM) and Tom70(ER-TM) were generated, namely rTom70(∆TM) and rTom70(ER-TM). Neither of these proteins could rescue the expression of IFN-β induced by SeV, after the endogenous Tom70 was knocked down ( Figure 5F ). Collectively, these data indicated that Tom70 interacts specifically with MAVS during RNA viral infection. It is necessary for both the proteins to localize on the mitochondria for mediating the antiviral responses.
Tom70 recruits TBK1/IRF3 to mitochondria by binding to Hsp90
Recently, we reported that chaperone Hsp90, IRF3 and TBK1 were constitutively in a protein complex [28] . In addition, a recent study suggested that Hsp90 could deliver a subgroup of mitochondrial pre-proteins, synthesized in the cytosol, to Tom70 for further sorting into mitochondrial compartments [25] . In light of our above results, we speculated that Tom70 could dynamically recruit TBK1/IRF3 to mitochondria by interacting with Hsp90. To address this hypothesis, ectopically expressed Hsp90 was confirmed to bind Tom70 ( Figure 6A lower left panel), and Hsp90 also interacted with IRF3 and TBK1 ( Figure 6A lower left panel) .
It was suggested that the clamp and core domain of Tom70 ( Figure 5C ) were responsible for the binding to Hsp90 and mitochondrial pre-proteins, respectively. We mapped the clamp domain of Tom70 and C-terminal motif of Hsp90 to mediate this interaction (data not shown). In addition, Hsp90 consists serially of three domains ( Figure 6A upper panel) . The N-terminal domain contains an ATP-binding site, while the middle domain displays high affinity for its client proteins. Consequently, several mutants of Tom70 and Hsp90 were generated as described, so that Tom70(R192A) had a point mutation in the clamp domain ( Figure 5C ), while the EEVD motif of Hsp90 was mutated to EEAA for Hsp90(2A) or truncated for Hsp90(∆4) ( Figure 6A upper panel) . We confirmed that the sub-cellular locations of Tom70(R192A) remained the same as the wild-type ( Figure 1D ). Therefore, wild-type or mutant forms of HA-Hsp90 and FlagTom70 were ectopically expressed in different combina- tions and subjected to co-immunoprecipitation assay. It was revealed that Flag-Tom70(R192A) did not interact with HA-Hsp90; conversely, neither HA-Hsp90(2A) nor HA-Hsp90(∆4) could interact with Flag-Tom70 ( Figure  6A lower right panel) .
Endogenously, Tom70 interacted strongly with Hsp90; Tom70 also co-immunoprecipitated with IRF3 and TBK1 ( Figure 6B ). In contrast, Tom20 did not bind to Hsp90, IRF3 or TBK1 ( Figure 6B ). To explore whether Hsp90 served as a bridge, we used RNAi strategy to effectively reduce the amount of endogenous Hsp90 (Supplementary information, Figure S5 ). It was found that the ability of Tom70 to co-immunoprecipitate IRF3 or TBK1 was apparently reduced when knocking down endogenous Hsp90 ( Figure 6C ). Conversely, IRF3 could barely coimmunoprecipitate with Tom70 upon decrease of endogenous Hsp90 expression ( Figure 6D ).
To recapitulate the observations in vitro, GST pulldown assay was performed using wild-type or mutant forms of recombinant Hsp90, Tom70 and IRF3 proteins. First, we pulled down His-IRF3 with wild-type or mutant forms of GST-Hsp90. As shown in Figure 6E upper left panel, Hsp90 interacted directly with His-IRF3. Perturbation of the Hsp90 C-terminal motif (GST-Hsp90(2A) and GST-Hsp90(∆4)) did not affect its binding to IRF3. Then, we confirmed the direct interaction between HisHsp90 and GST-Tom70(∆TM). Notably, point mutants of either Tom70(R192A) or Hsp90(2A) failed to interact directly with the reciprocal wild-type proteins, which was consistent with the above in vivo results ( Figure 6E upper right panel). Finally, we tested whether Hsp90 was critical to mediate the association between Tom70 and IRF3 in vitro. As expected, in the presence of Hsp90, wild-type GST-Tom70(∆TM) could pull down His-IRF3. However, when crippling the direct interaction between GST-Tom70(∆TM) and His-Hsp90 by using the corresponding mutants, it was found that Tom70 completely failed to pull down IRF3 ( Figure 6E lower panel) . Taken together, these data indicated that Tom70 recruits TBK1/ IRF3 via Hsp90, both in vivo and in vitro.
The direct interaction between Tom70 and Hsp90 is essential for IRF3 activation
To further explore the physiological relevance of this direct interaction, we observed that Tom70(R192A), which was deprived of the ability to bind Hsp90, could not potentiate the expression of IRF3-responsive reporters stimulated by SeV infection or poly(I:C) (Supplementary information, Figure S1C and S1D), although Tom70(R192A) was expressed similarly to wild-type Tom70 on mitochondria ( Figure 1D) . Similarly, the induction of IRF3-mediated endogenous genes by SeV or poly(I:C) was not enhanced by ectopically expressing this Tom70 mutant in either HEK293 or primary cells (BMDM or BMDC; Figure 2A-D) . Moreover, rTom70(R192A), the corresponding RNAi-resistant construct, failed to rescue IFN-β expression induced by SeV, after attenuating endogenous Tom70 expression ( Figure  5F ).
We confirmed that decrease in endogenous Hsp90 expression by siRNA resulted in significant reduction of the IFN-β gene transcription induced by SeV infection or poly(I:C) transfection ( Figure 6F ). We also ruled out the potential off-target effects of the Hsp90 siRNA by demonstrating that rHsp90, the RNAi-resistant wildtype Hsp90, could restore SeV-stimulated IFN-β mRNA Figure 6G ). Then, we generated RNAi-resistant Hsp90 mutants in the background of Hsp90(2A) and Hsp90(∆4), namely rHsp90(2A) and rHsp90(∆4), so that rHsp90(2A) and rHsp90(∆4) could remain intact when knocking down endogenous Hsp90, whereas they expressed the same protein as Hsp90(2A) and Hsp90(∆4), respectively. Obviously, neither rHsp90(2A) nor rHsp90(∆4) could bind to Tom70. Consistent with this, it was observed that neither rHsp90(2A) nor rHsp90(∆4) could rescue the expression of IFN-β mRNA stimulated by SeV, when knocking down endogenous Hsp90 ( Figure 6G ). 
Tom70 enhances IRF3-mediated antiviral responses
Finally, we studied the physiological function of Tom70 during primary host antiviral responses. It is well known that the induction of IFN-β is a hallmark of host antiviral abilities. To explore whether Tom70 regulates the production of IFN-β, we transfected Tom70, Tom70(R192A) or Tom20 into HEK293 cells followed by SeV treatment. Using enzyme-linked immunosorbent assay (ELISA), we observed that Tom70 could significantly promote IFN-β protein production, whereas neither Tom70(R192A) nor Tom20 was able to do so ( Figure  7A ). Furthermore, knockdown of endogenous Tom70 by introduction of siRNA to HEK293 cells drastically impaired IFN-β protein production upon SeV infection, whereas knockdown of Tom20 had no apparent inhibitory effect ( Figure 7B ). As another control, Tom70mt siRNA did not affect IFN-β expression either ( Figure  7B) .
As IFN-β could protect cells from infection, we assessed whether Tom70 played a role in virus restriction. HEK293 cells were transfected with indicated plasmids ( Figure 7D ) or siRNA ( Figure 7E ), and then infected with SeV. The culture supernatants from these cells were used to pre-treat fresh HEK293 cells followed by vesicular stomatitis virus (VSV) infection. It was found that knockdown of Tom70 made cells more sensitive to VSV infection ( Figure 7E ), whereas ectopic expression of Tom70 could protect cells from VSV infection ( Figure  7D ).
We next investigated whether Tom70 modulated viral replication by challenging the cells directly with VSV or Newcastle disease virus-green fluorescent protein (NDV-GFP). HEK293 cells transfected with indicated siRNA were treated with VSV for 16 h, and then the titers of VSV were analyzed by standard plaque assay. As shown in Figure 7C , Tom70 knockdown resulted in a significant increase in virus titer compared to controls. For NDV-GFP infection, exogenous expression of Tom70 significantly suppressed NDV-GFP viral replication in HEK293 cells, whereas overexpression of either Tom70(R192A) or Tom20 had no such function ( Figure 7F ). Furthermore, depletion of Tom70 markedly augmented the levels of NDV-GFP-positive cells. In contrast, knockdown of Tom20 displayed no apparent increase in NDV-GFP infection ( Figure 7G ). Conclusively, these data indicate that Tom70 serves as a positive regulator of IRF3 activation and it promotes host antiviral responses during virus infection.
Discussion
During the past several years, a new paradigm is proposed that RIG-I-like helicases and Toll-like receptors (TLRs) detect RNA viruses from topologically intra-and extracellular compartments and initiate immediate host defense to restrict virus infection and proliferation. Simultaneously, cytokines and chemokines are induced to mobilize immune cells to prevent pathological infection and to eliminate invasive virus. An important outcome of RIG-I antiviral signal transduction is the rapid and robust induction of type-I interferons (in particular IFN-β) , in which the pivotal process is to activate protein kinase TBK1 and transcription factor IRF3 through the MAVS signal complex on the mitochondrial outer membrane.
Interestingly, MAVS per se localizes on the outer membrane of mitochondria via its C-terminal transmembrane domain (TM) [11] . In contrast, the rest of the reported components in the MAVS signal complex reside in the cytosol. TRAF3 associates with MAVS after dimerization of the MAVS [33] . Consequently, TRAF3 could catalyze the formation of K63 poly-ubiquitin. This process is attenuated by de-ubiquitinase DUBA [34] . In addition, MAVS is recently reported to be modified by both K63 and K48 poly-ubiquitin [21] . Ubiquitination plays both positive and negative roles in regulating the MAVS signal complex [22, 35] . The relevant molecular mechanisms need further investigation. TRADD and TANK are also reported to be the components of MAVS complex after virus infection. However, a recent study questions the possible role of TANK in RIG-I signaling [36] .
Notably, a critical missing link exists as to how MAVS signal complex relays activation signal to TBK1 and IRF3. We hypothesized that there might be unknown adaptor protein(s) on mitochondria to fill this gap. By proteomics approach, we identify Tom70 as the candidate adaptor on mitochondrial outer membrane. Several lines of evidence in this study substantiate the critical function of Tom70 in RIG-I signaling. First, exogenous expression of Tom70 potentiates the induction of IRF3-responsive genes upon SeV infection or poly(I:C) transfection, but does not affect the TRIF-mediated IRF3 activation. Second, knockdown of Tom70 unequivocally results in the significant reduction of IRF3-mediated gene expressions, and this attenuation could be rescued by exogenously expressing a siRNA-resistant rTom70. Third, the kinase activity of TBK1 and the phosphorylation of IRF3 are apparently impaired when knocking down endogenous Tom70 during virus infection, indicating that Tom70 functions upstream of TBK1. Fourth, Tom70 interacts with MAVS. This interaction increases markedly upon virus challenge. Mislocation of Tom70 to either cytosol or ER abolishes its potentiating activity towards IRF3 activation. RNAi-resistant mutants of these Previously, we reported that the N-terminal domain of Hsp90 interacted with both TBK1 and IRF3 in resting cell [28] . Disrupting the binding of Hsp90 to TBK1 immediately caused ubiquitin-proteasome-mediated degradation of TBK1. Intriguingly, we observed that the C-terminal truncation mutant of Hsp90(1-620 aa) could bind to TBK1 and IRF3 [28] . However, Hsp90(1-620 npg aa) acted as strong dominant-negative mutant for TBK1 activation, suggesting that Hsp90 may link TBK1 and IRF3 to the upstream signaling protein(s). In this study, the clamp domain of Tom70 is uncovered to specifically interact with the C-terminal motif (EEVD) of Hsp90. The importance of this unique interaction is supported by several lines of evidence. Tom70(R192A) does not bind to Hsp90 both in vitro and in vivo, although it is expressed on mitochondria similarly to the wild-type Tom70. Consistently, neither Tom70(R192A) could potentiate IRF3 activation, nor could its RNAi-resistant mutant rTom70(R192A) rescue the expression of IFN-β in Tom70 knockdown cells. Conversely, the Hsp90(2A) and Hsp90(∆4), which are deprived of the ability to bind Tom70, display the same effect as Tom70(R192A). Furthermore, mislocation of Tom70 impairs the activation of TBK1 and IRF3. In conclusion, Tom70 has a novel and essential function in host primary antiviral responses. Interestingly, Hsp90 was reported to interact strongly with the IKK complex [37] . We confirmed this observation. In addition, we found that Tom70 could immunoprecipitate IKK complex in the presence of Hsp90 (unpublished data; Liu and Wei), indicating that a similar theme applies to the activation of IKK. In light of our current study, a tentative model, on the action of Tom70 is proposed, that Tom70 recruits both TBK1/IRF3 and IKK complex to mitochondria by specifically recognizing Hsp90, thus linking MAVS to its downstream signaling events (Figure 8 ). It is a great challenge to elucidate the molecular dynamics of the MAVS/Tom70 signaling complex in future investigations. Recent studies have revealed two mitochondrial proteins MAVS (also called IPS-1, VISA and Cardif) and NLRX1 to modulate antiviral signal transduction [9] [10] [11] [12] 38] . It is still controversial whether a third protein STING/MITA is localized on mitochondria [30, 31] . An unresolved issue is that why mitochondria is selected as the platform to initiate intracellular antiviral signaling. In the cytosol of resting cells, RIG-I is autorepressed in a closed conformation, whereas Hsp90/TBK1/IRF3 form a protein complex constitutively. Upon RNA virus infection, RIG-I binds to double-stranded RNA (dsRNA), which causes RIG-I to undergo dramatic conformational change and results in the exposure of its N-terminal CARD domains (1). Therefore, RIG-I associates with the adaptor protein MAVS on the outer membrane of mitochondria through CARD-CARD homotypic interaction (2). In turn, this triggers MAVS to interact more strongly with Tom70 via their transmembrane domains (3) . At the same time, Hsp90 delivers TBK1/IRF3 to mitochondria, via clamp domain of Tom70 and EEVD motif of Hsp90 (4). Transiently, this leads to the formation of a stable signal complex on the mitochondrial outer membrane, including MAVS/Tom70/Hsp90/TBK1/IRF3, inducing a temporary surge of the local concentration of TBK1. Consequently, activated TBK1 phosphorylates the transcription factor IRF3 (5). Ultimately, phosphorylated IRF3 dissociates from the complex and translocates into nucleus to promote antiviral gene transcription (6) . Similarly, Hsp90 binds strongly to and delivers IKK complex to Tom70, thus resulting in the activation of IKK and NF-κB. The current insight from Tom70 will probably provide a new clue as to the necessity of forming the signal complex on mitochondria. As Tom70 is conserved from yeast to human, we speculate that the ancient function of Tom70 was dedicated exclusively to recognize a subgroup of mitochondrial proteins synthesized in the cytosol. Probably, evolution took advantage of the unique mechanism that Tom70 sorts mitochondrial proteins by interacting with Hsp90, in contrast to Tom20 that recognizes a specific signal peptide on the target proteins. In due time, Hsp90 constitutively forms a protein complex with TBK1 and IRF3. Consequently, this protein complex is integrated into innate immunity and recruited to mitochondria for further elaboration of the signal transduction. It will be intriguing to explore when Tom70 gained this new function during the evolution of animal kingdom.
Materials and Methods
Plasmids
Human full-length IRF3, TBK1, Hsp90, MAVS and Tom70 cDNAs were cloned from human thymus plasmid cDNA library (Clontech) using standard PCR techniques and then sub-cloned into indicated vectors. All point mutants were generated by using a Quickchange XL (Stratagene). Tom70(ΔTM) is deprived of its Nterminal transmembrane domain (1-60 aa), while Tom70(ER-TM) replaces its N-terminal transmembrane domain (1-100 aa) with an ER targeting sequence (180 aa). Hsp90(Δ4) is truncated of the last four amino acids EEVD at its C-terminus, while Hsp90(2A) has the last two amino acids VD changed to AA at its C-terminus. MAVS(ΔTM) is truncated of its C-terminal transmembrane domain (514-540 aa). All Tom70 siRNA-resistant forms were generated by introducing silent mutations in the Tom70 siRNA target sequence (1453-GCG CTG ACG GAC CAG CAA-1470). All Hsp90 siRNA-resistant forms were generated by introducing silent mutations in the Hsp90 siRNA target sequence (1181-GTG ACA AAA AAA AAA AAA AG-1200). All constructs were confirmed by sequencing. pEGFP-mito for labeling mitochondria was kindly provided by Dr Jiansheng Kang (Shanghai Institute for Biological Sciences, SIBS); β-catenin and TOPflash luciferase reporters were provided by Dr Lin Li (SIBS). 
Antibodies
Mouse polyclonal antibody against human Tom70 recombinant protein spanning 110-608 aa was generated in this lab. This antibody was purified by affinity column conjugated with recombinant Tom70 protein, and its specificity was confirmed. Antibodies obtained from commercial sources were as follows: anti-Flag, anti-β-actin (Sigma); anti-HA, anti-GST, anti-His, anti-IRF3, anti-PARP (Santa Cruz); anti-Hsp90, anti-Tom20 (Proteintech); anti-calnexin, anti-phospho-IRF3(pS386) (Epitomics); anti-TBK1 (Millipore) and anti-MAVS (CST).
Luciferase reporter assays
Luciferase reporter assays were performed as described previously [28] .
Q-PCR
At 24-48 h after transfection of indicated siRNA or plasmids, HEK293 cells were stimulated with SeV infection for 8 h or poly(I:C) transfection for 16 h. Total cellular RNA was isolated with TRIzol (Invitrogen) according to manufacturer's instruction. Reverse transcription of purified RNA was performed using oligodT primer. The quantification of gene transcripts was performed by Q-PCR using SYBR green I dye. All values were normalized to the level of β-actin mRNA. The primers used were listed in Table 1 .
Cell culture
HEK293T and HEK293 cells were cultured using DMEM plus 10% FBS, supplemented with 1% penicillin-streptomycin (Gibco-BRL). Transient transfection was performed with lipofectamine 2000 (Invitrogen) following manufacturer's instructions.
Manipulation of primary cells
BMDCs were generated according to the culture method published previously [39] . BMDMs were obtained as described [29] with minor modifications. BMDM and BMDC were harvested after about 6-10 days and cultured in 12-well plates for siRNA transfection using lipofectamine 2000 or transfected directly with the nucleofactor kit (Amaxa) before culturing further. For peritoneal macrophages, 3 days after injection of 2 ml of 4.0% (wt/vol) thioglycollate medium (Sigma), peritoneal cells were isolated from the peritoneal cavities of mice by peritoneal lavage with PBS. Macrophages were collected after washing twice with PBS and were resuspended in DMEM containing 10% FBS in 12-well plates for further RNAi experiments.
Sub-cellular fractionation
HEK293 cells were washed with cold PBS and lysed by douncing in homogenization buffer (buffer H: 210 mM sucrose, 70 mM mannitol, 1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl 2 , 10 mM Hepes (pH 7.2), protease inhibitor cocktail). The homogenate was centrifuged at 500× g for 10 min and the pellet (P0) was saved as crude nuclei. The supernatant (S0) was centrifuged at 5 000× g for 10 min to precipitate crude mitochondria (P5). The supernatant (S5) was further centrifuged at 50 000× g for 10 min to generate S50 and P50. Each pellet was resuspended in buffer H for later experiments. 
Protein purification and mass spectrometry
At 36 h after transfection of Flag-MAVS, HEK293T cells were stimulated by SeV for 2 h, and then collected and fractionated. The mitochondria pellet fraction was lysed with NP40 buffer (buffer N: 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM PMSF, 0.1% (v/v) NP40, protease inhibitor cocktail). Post-centrifuged supernatants were pre-cleared with protein A/G beads and control IgG for 0.5 h at 4 °C. Pre-cleared lysates were mixed with 1-2 µg of mouse antiFlag antibody for 1 h at 4 °C. Then protein A/G beads were added and the mixtures were incubated for 2 h at 4 °C. Precipitates were washed extensively with Buffer N. Proteins bound to protein A/ G beads were separated on 7.5% SDS-PAGE. After silver staining (Sigma), specific protein bands were excised and analyzed by iontrap mass spectrometry.
Immunoblot analysis and immunoprecipitation assay
For immunoblotting, the immunoprecipitates or whole-cell lysates were resolved by SDS-PAGE and transferred to a PVDF membrane (Millipore). Immunoblotting was probed with indicated antibodies. The proteins were visualized by using Supersignal West Pico chemiluminescence ECL kit (Pierce). For immunoprecipitation, cells were collected about 24-48 h after transfection and then lysed in Buffer N or sonicated in TBS buffer supplemented with a complete protease inhibitor cocktail (Roche). Then the whole-cell lysates were used for immunoprecipitation with indicated antibodies. Generally, 0.5-1 µg of commercial antibody was added to 500 µg of cell lysate and then incubated for 1-2 h at 4 °C. After addition of protein A/G beads, the incubation was continued for 2-10 h. Immunoprecipitates were extensively washed with Buffer N and eluted with SDS loading buffer by boiling for 5 min.
GST pull-down assays
For GST pull-down assay, 0.25-1 µg of indicated recombinant proteins in buffer N were incubated with 15 µl of Glutathione Sepharose 4B (GE Healthcare) for 1 h at 4 °C. After washing three times with Buffer N, pellets were analyzed on SDS-PAGE and subjected to immunoblotting analysis.
Confocal imaging
HEK293T cells were plated on coverslips in 12-well plates and transfected with the indicated siRNA or plasmids. To label mitochondria in a specific experiment, cells were incubated with 250 nM MitoTracker Red (Molecular Probes) for 30 min at 37 °C. Coverslips with the cells were washed once with PBS and fixed in 3.7% formaldehyde in PBS for 15 min. Cells were permeabilized and blocked for 30 min at room temperature in a staining buffer containing Triton X-100 (0.1%) and BSA (2%), and then incubated with a primary antibody in the staining buffer lacking Triton X-100 for 1 h. After washing three times in the staining buffer lacking Triton X-100, cells were incubated with a secondary antibody for 1 h and then with DAPI for 10 min. The coverslips were then washed extensively and fixed on slides. Imaging of the cells was carried out using Leica laser scanning confocal microscopy.
Mitochondrial TMRM staining
For stock solution, both CCCP (Sigma) and TMRM (Biotium) were dissolved in dimethylsulfoxide (DMSO; Sigma) to obtain 50 mM concentration and stored at −20 °C. HEK293T cells were plated onto four Willco dishes; two dishes were transfected with the indicated siRNAs for 2 days; the other two dishes were treated with either CCCP or DMSO for 3 h. All cells were co-transfected with EGFP-mito plasmids to label mitochondria. After incubating at 37 °C in the dark with 10 µM TMRM for 30 min, the cells were washed with DMEM (no phenol red) and imaged by Leica laser scanning confocal microscopy.
Rescue experiments
HEK293 cells were first treated with Tom70 or Hsp90 siRNA for 12 h and then transfected again with the indicated siRNAresistant Tom70 or Hsp90 plasmids, followed by SeV infection the next day. 
Kinase assay
For each reaction, 500 µg of cell lysate was incubated at 4 °C for 1 h with anti-TBK1 antibody (4 µl) conjugated with protein A/ G bead slurry (10 µl). Immunoprecipitates were washed twice with buffer N and three times with buffer K (20 mM HEPES (pH 7.2), 50 mM NaCl, 10 mM MgCl 2 and 0.1 mM EDTA). Then, the beads were incubated at 37 °C for 30 min in 20 µl of the buffer K containing γ-32 P-ATP (5 µCi), ATP (100 µM) and GST-IRF3 (1.0 µg). After SDS-PAGE, the phosphorylation of IRF3 was visualized by autoradiography.
Measurement of IFN-β production
HEK293 cells were transfected with the indicated plasmids or siRNA, and then cell culture supernatants were collected at 8 h after virus infection and analyzed for IFN-β production using ELISA kits (PBL Biomedical Laboratories) according to manufacturer's instructions.
Virus manipulation
Viral infection was performed when 80% cell confluence was reached. Then, culture media was replaced by serum-free DMEM, and SeV, VSV or NDV-GFP was added to the media at MOI 0.2-1 according to specific experiments. After 1 h, the medium was removed and the cells were fed with DMEM containing 10% FBS.
Statistics
Student's t-test was used for the comparison of two independent treatments. For all tests, a P value < 0.05 was considered statistically significant.
